These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24849323)

  • 21. Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy).
    Ruwald MH; Abu-Zeitone A; Jons C; Ruwald AC; McNitt S; Kutyifa V; Zareba W; Moss AJ
    J Am Coll Cardiol; 2013 Oct; 62(15):1343-50. PubMed ID: 23770172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Incidence and causes of nonresponse to cardiac resynchronization therapy in patients with congestive heart failure].
    Wang DM; Han YL; Zang HY; Yu HB; Zhou WW; Zhang DH; Tian Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Oct; 38(10):895-900. PubMed ID: 21176632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study.
    Auricchio A; Delnoy PP; Butter C; Brachmann J; Van Erven L; Spitzer S; Moccetti T; Seifert M; Markou T; Laszo K; Regoli F;
    Europace; 2014 May; 16(5):681-8. PubMed ID: 24497573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
    Goldenberg I; Hall WJ; Beck CA; Moss AJ; Barsheshet A; McNitt S; Polonsky S; Brown MW; Zareba W
    J Am Coll Cardiol; 2011 Aug; 58(7):729-37. PubMed ID: 21816309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absolute survival after cardiac resynchronization therapy according to baseline QRS duration: a multinational 10-year experience: data from the Multicenter International CRT Study.
    Gasparini M; Leclercq C; Yu CM; Auricchio A; Steinberg JS; Lamp B; Klersy C; Leyva F
    Am Heart J; 2014 Feb; 167(2):203-209.e1. PubMed ID: 24439981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whom should I refer in 2014 for cardiac resynchronization?
    Manlucu J; Tang AS
    Can J Cardiol; 2014 Jun; 30(6):675-8. PubMed ID: 24882541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.
    Chen S; Ling Z; Kiuchi MG; Yin Y; Krucoff MW
    Europace; 2013 Jul; 15(7):992-1001. PubMed ID: 23419662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival in cardiac resynchronization therapy. What do we know?
    Préda I
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():57-9. PubMed ID: 17584682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy.
    Gold MR; Leman RB; Wold N; Sturdivant JL; Yu Y
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):624-30. PubMed ID: 24446891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker.
    Schuchert A; Muto C; Maounis T; Frank R; Boulogne E; Polauck A; Padeletti L;
    Europace; 2013 Jan; 15(1):71-6. PubMed ID: 22927665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of cardiac resynchronization therapy on hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure trial.
    Gillis AM; Kerr CR; Philippon F; Newton G; Talajic M; Froeschl M; Froeschl S; Swiggum E; Yetisir E; Wells GA; Tang AS
    Circulation; 2014 May; 129(20):2021-30. PubMed ID: 24610807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
    Martin DT; McNitt S; Nesto RW; Rutter MK; Moss AJ
    Circ Heart Fail; 2011 May; 4(3):332-8. PubMed ID: 21350054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis.
    Chen S; Yin Y; Krucoff MW
    Europace; 2012 Nov; 14(11):1602-7. PubMed ID: 23104857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
    Pires LA; Abraham WT; Young JB; Johnson KM;
    Am Heart J; 2006 Apr; 151(4):837-43. PubMed ID: 16569543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cardiac resynchronization therapy-defibrillator implantation on health status in patients with mild versus moderate symptoms of heart failure.
    Versteeg H; van den Broek KC; Theuns DA; Mommersteeg PM; Alings M; van der Voort PH; Jordaens L; Pedersen SS
    Am J Cardiol; 2011 Oct; 108(8):1155-9. PubMed ID: 21821227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of ventricular arrhythmias in patients with cardiac resynchronization therapy without back-up ICD: a single-center experience.
    Bortnik M; Degiovanni A; Dell'era G; Cavallino C; Occhetta E; Marino P
    J Cardiovasc Med (Hagerstown); 2014 Apr; 15(4):301-6. PubMed ID: 23811840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure.
    Brenyo A; Barsheshet A; Rao M; Huang DT; Zareba W; McNitt S; Hall WJ; Peterson DR; Solomon SD; Moss AJ; Goldenberg I
    Circ Heart Fail; 2013 Sep; 6(5):998-1004. PubMed ID: 23801020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias.
    Manfredi JA; Al-Khatib SM; Shaw LK; Thomas L; Fogel RI; Padanilam B; Rardon D; Vatthyam R; Gemma LW; Golden K; Prystowsky EN
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):257-64. PubMed ID: 23443618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential predictors of non-response and super-response to cardiac resynchronization therapy.
    Qiao Q; Ding LG; Hua W; Chen KP; Wang FZ; Zhang S
    Chin Med J (Engl); 2011 May; 124(9):1338-441. PubMed ID: 21740744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.